PRELIMINARY PROGRAM
(as of May 15, 2025)

Developing RNA based approaches for the treatment of Pompe Disease and neurodegenerative conditions
Emanuele Buratti
Group Leader, Molecular Pathology Lab, **ICGEB**, Italy

Breast cancer transcriptomics at the bulk, single cell and spatial levels
Carlos Caldas
Honorary Consultant-Medical Oncology, **University of Cambridge**, UK

Utilizing Machine Learning to Unlock RNA Delivery
Yogev Debbi
Co-Founder & CEO, **Mana.bio**, IL



Ultra-conserved poison exons in SR protein splicing regulator genes: do these operate as tumour suppressors or protect the functions of specific cell types?
David Elliott
Principal Investigator, **University of Newcastle**, UK

DELiveri: Massive throughput screens to identify conjugates that promote cell delivery of nucleic acid therapeutics
Yaniv Erlich
CEO and Co-founder, **Eleven Therapeutics**, IL

RNA-binding proteins in melanoma progression
Fátima Gebauer
President of the **RNA Society** and Principal Investigator, **Center for Genomic Regulation (CRG)**, Spain

---

A novel regulatory circuit required for tumor angiogenesis and cancer growth
Claudia Ghigna
Scientist, **Institute of Molecular Genetics**, Italy

AI-Driven Design: Unlocking Novel Mechanisms in RNA Therapeutics
Tamar Grossman
CEO, **La Jolla Labs**, USA

Nucleic Acid Therapeutic Unlabeled Reporter Assay (NATURA): A novel platform for high-throughput quantification of NATs' functional delivery and potency
Ernesto Guccione
Principal Investigator, The Guccione Lab, **Icahn School of Medicine at Mount Sinai**, USA

Targeting RNA precessng to induce neoantigens in cancer cells
Rotem Karni
Principal Investigator
Hebrew University-Hadassah Medical School, Jerusalem, IL, and **University of Pennsylvania**, USA

Bispecific siRNA to Reduce Cardiometabolic Risk
Michael Khan
CEO, **Argonaute RNA**, UK

SpliSense – A transformative RNA (ASOs) based company for the treatment of Pulmonary diseases
Gili Hart
SpliSense, IL

SRSF1-regulated alternative splicing controls on oncogenic circuit in pancreatic cancer
Adrian Krainer
Cold Spring Harbor Laboratory, New York, USA

Dual-function oligonucleotide strategies for immunotherapy of acute myeloid leukemia
Marcin Kortylewski
Principal Investigator, **The Kortylewski Lab City of Hope**, USA

Exploiting the dark genome to target drug-tolerant cells and improve anticancer immune therapies
Eleonora Leucci
Principal Investigator – RNA Cancer Biology Lab, **KU Leuven**, Belgium

---

Rewriting the Message: RNA Splice Disruption Unmasks New Cancer Immunotherapy Targets
Michal Lotem
Head of The Hadassah Cancer Research Institute (HCRI),
Hadassah Hebrew University Medical Center, Jerusalem, IL

Targeting m6A-RNA Biology in FTO-Dependent Cancers
Amir Mor
CSO, **RNAble**, IL

Improved Delivery of RNAs for Extra-Hepatic Delivery
Ruben Postel
CSO & Scientific Founder, **Sapreme Technologies**, The Netherlands

---

Harnessing RNA-Driven Intelligence to Revolutionize Personalized Cancer Therapy
Aron Popovtzer
Director of the Sharett Institute of Oncology, **Hadassah Medical Center**, Jerusalem, IL

Therapeutic approaches for HNRNPH2-Related Neurodevelopmental Disorder, an ultra-rare neurogenetic disorder
Christopher Ricupero
Assistant Professor, **Columbia University Irving Medical Center**, USA

Exploiting RNA translation control to fight cancer resistance
Caroline Robert
Head of Dermatology, **Gustave Roussy Institute**, France

Translation dysregulation in cancer as a source for targetable antigens
Yardena Samuels
Director, Moross Integrated Cancer Center, Samuels Lab, **Weizmann Institute of Science**, IL

Modeling and modulating antitumor immunity with RNA nanoparticles in 3D-bioprinted tumoroids
Ronit Satchi-Fainaro
Director, Cancer Biology Research Center, and Director, TAU Kahn 3D BioPrinting Initiative, **TAU**, IL

Splicing dysregulation: hallmark and therapeutic opportunity in cancer
Claudio Sette
Principal Investigator, **Catholic University of the Sacred Heart, School of Medicine**, Italy

---

Pseudoexon activation as a therapeutic approach
Brage Storstein Andresen
Head of Research, Brage Storstein Andresen Lab, **University of Southern Denmark**

Aberrantly spliced cancer proteoforms: if you can't beat them, eat them!
Andrei Thomas-Tikhonenko
Director of Experimental Pathology, **Children's Hospital of Philadelphia**, USA

Targeting noncoding elements to boost haploinsufficient gene expression
Igor Ulitsky
Principal Investigator, Ulitsky Lab, **Weizmann Institute of Science**, IL

miRNA-based logic circuits encoded on self-amplifying RNA for highly specific cancer cell classification
Ron Weiss
Principal Investigator, The Weiss Lab, **Massachusetts Institute of Technology**, Boston, USA

Targeting RNA splicing in immuno-oncology and beyond
Thomas Westbrook
Executive Director, Therapeutic Innovation Center, **Baylor College of Medicine**, USA

For further information, please visit our website:

https://rnahorizons.com/